Natco Pharma on November 12 said its consolidated net profit jumped 83 percent on-year to Rs 676 crore in the September 2024 quarter, aided by robust sales.
The drug maker reported a net profit of Rs 369 crore in the July-September period of last fiscal.
Revenue from operations rose to Rs 1,371 crore as compared with Rs 1,031 crore in the year-ago period, Natco Pharma said in a regulatory filing.
"The company has shown continued strong growth during the second quarter driven by exports formulation business and stable domestic pharmaceutical business," it stated.
Natco Pharma's board has declared a second interim dividend of Rs 1.5 per equity share of Rs 2 each for financial year 2024-25.
Shares of the drug firm ended 0.19 percent down at Rs 1,393.15 apiece on the BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
